WallStreetZenWallStreetZen

NASDAQ: ANTX
An2 Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ANTX earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$64.7M
Current Profit Margin
0%

ANTX Return on Equity

Current Company
-59.7%
Current Industry
-63.5%
Current Market
188%
ANTX's Return on Equity (-59.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ANTX announces earnings.

ANTX Return on Assets

Current Company
-53.7%
Current Industry
2.9%
ANTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ANTX Return on Capital Employed

Current Company
-51.91%
Current Industry
19.5%
ANTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ANTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ANTX$0.00-$64.68M-$64.73MN/AN/A
HOOK$20.13M-$77.34M-$81.58M+21.41%N/A
CRVS$0.00-$26.88M-$27.03MN/AN/A
TIL$0.00-$145.48M-$156.09M-100.00%N/A
ANEB$0.00-$10.46M-$10.49MN/AN/A
View Top Biotech Stocks

ANTX earnings dates

Next earnings date
May 8, 2024

An2 Therapeutics Earnings & Revenue FAQ

What were ANTX's earnings last quarter?

On Invalid Date, An2 Therapeutics (NASDAQ: ANTX) reported Q4 2023 earnings per share (EPS) of -$0.52, up 10.34% year over year. Total An2 Therapeutics earnings for the quarter were -$16.90 million. In the same quarter last year, An2 Therapeutics's earnings per share (EPS) was -$0.58.

If you're new to stock investing, here's how to buy An2 Therapeutics stock.

What was ANTX's earnings growth in the past year?

As of Q2 2024, An2 Therapeutics's earnings has grown year over year. An2 Therapeutics's earnings in the past year totalled -$64.73 million.

What is ANTX's earnings date?

An2 Therapeutics's earnings date is Invalid Date. Add ANTX to your watchlist to be reminded of ANTX's next earnings announcement.

What was ANTX's revenue last quarter?

On Invalid Date, An2 Therapeutics (NASDAQ: ANTX) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, An2 Therapeutics's revenue was $0.00.

What was ANTX's revenue growth in the past year?

As of Q2 2024, An2 Therapeutics's revenue has grown null year over year. An2 Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.